MedTrace Logo

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

NCT01151215 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 482

Last updated 2014-07-25

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to compare progression free survival in patients treated with AZD8931 given in combination with anastrozole versus anastrozole alone. The secondary objective is to investigate the safety and tolerability of AZD8931 given in combination with anastrozole.

Conditions

Interventions

DRUG

AZD8931

Tablet, oral, bd

DRUG

anastrozole

Tablet, oral, od

DRUG

Placebo

Tablet, oral

Sponsors & Collaborators

Principal Investigators

  • Dr Serban Ghiorghiu, MD · AstraZeneca

  • Stephen Johnston, MA, PhD, FRCP · The Royal Marsden Hospital, London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States
  • Brazil
  • Canada
  • Czechia
  • Finland
  • India
  • Japan
  • Mexico
  • Peru
  • Philippines
  • Poland
  • Russia
  • South Africa
  • South Korea
  • Taiwan
  • Thailand
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01151215 on ClinicalTrials.gov